36
Participants
Start Date
November 30, 2007
Primary Completion Date
October 31, 2010
Study Completion Date
March 31, 2011
IMO-2055
0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
New York Oncology Hematology P.C., Albany
Virginia Oncology Associates, Norfolk
Cancer Centers of Florida, Ocoee
Central Indiana Cancer Centers, Indianapolis
Mary Crowley Medical Research Center, Dallas
Tyler Cancer Center, Tyler
Cancer Therapy and Research Center, San Antonio
Northwest Cancer Specialists, Vancouver
Yakima Valley Memorial Hospital/North Shore Cancer Lodge, Yakima
Lead Sponsor
EMD Serono
INDUSTRY